HC Wainwright & Co. Reiterates Buy on Cardiol Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Cardiol Therapeutics (NASDAQ:CRDL) with a maintained price target of $9.

May 14, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Cardiol Therapeutics with a $9 price target, indicating a positive outlook on the stock.
The reiteration of a Buy rating by a reputable analyst firm like HC Wainwright & Co., along with a maintained price target, suggests a strong belief in the company's future performance. This endorsement could lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100